Pharmacotherapeutic management of pulmonary arterial hypertension

Cardiology in Review

Volumn 18, Issue 3, 2010, Pages 148-162

  Anderson, Joe R ^a   Nawarskas, James J ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

Endothelin receptor antagonists; Phosphodiesterase type 5 inhibitors; Prostacyclin analogues; Pulmonary arterial hypertension; Rostacyclin

Indexed keywords

ADCIRCA; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMBRISENTAN; AMIODARONE; AMLODIPINE; AMPRENAVIR; BERAPROST; BOSENTAN; CYCLOSPORIN A; DILTIAZEM; ENDOTHELIN RECEPTOR ANTAGONIST; ERYTHROMYCIN; GLIBENCLAMIDE; GLYCERYL TRINITRATE; ILOPROST; KETOCONAZOLE; LOPINAVIR; PHENYTOIN; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; RIFAMPICIN; RITONAVIR; SILDENAFIL; SITAXSENTAN; TADALAFIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; UNIPROST; VARDENAFIL; VASOACTIVE INTESTINAL POLYPEPTIDE; VASODILATOR AGENT; WARFARIN;

ANEMIA; ASTHENIA; BACKACHE; BLURRED VISION; CATHETER THROMBOSIS; CELL PROLIFERATION; DEVICE INFECTION; DIARRHEA; DIZZINESS; DRUG MECHANISM; DYSPEPSIA; EDEMA; EPISTAXIS; FEVER; FLUSHING; HEADACHE; HEART PALPITATION; HUMAN; HYPOTENSION; INJECTION SITE PAIN; INSOMNIA; JAW DISEASE; LEG EDEMA; LEG PAIN; LIMB PAIN; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MYALGIA; NAUSEA; NOSE CONGESTION; PRURITUS; PULMONARY HYPERTENSION; QUALITY OF LIFE; RASH; REVIEW; SIDE EFFECT; SMOOTH MUSCLE FIBER; SYNCOPE; THORAX PAIN; THROMBOSIS; VASOCONSTRICTION; VASODILATATION; VOMITING;

ANTICOAGULANTS; CALCIUM CHANNEL BLOCKERS; DRUG THERAPY, COMBINATION; EPOPROSTENOL; HUMANS; HYPERTENSION, PULMONARY; PHOSPHODIESTERASE INHIBITORS; RECEPTORS, ENDOTHELIN;

EID: 77951443168     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/CRD.0b013e3181d4e921     Document Type: Review

References (122)

1. D'Alonzo GG, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a natural prospective registry. Ann Intern Med. 1991;115:343-349.
2. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173:1023-1030.
3. Peacock AJ, Murphy NF, McMurray JJ, et al. An epidemiological study of pulmonary arterial hypertension. Eur Respir J. 2007;30:104-109.
4. Thenappan T, Shah SJ, Rich S, et al. A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur Respir J. 2007;30:1103-1110. (Pubitemid 351194756)
5. Simonneau G, Galie N, Rubin L, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004;43(suppl):S5-S12.
6. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 1987;107:216-223. (Pubitemid 17137857)
7. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: A report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. J Am Coll Cardiol. 2009;53:1573-1619.
8. Badesch DB, Abman SH, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest. 2007;131:1917-1928.
9. Badesch DB, Champion HC, Gomez Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009; 54:S55-S66.
10. McGoon M, Gutterman D, Steen V, et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004;126:14S-34S.
11. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med. 2004;351:1655-1665.
12. Rubin LJ. Primary pulmonary hypertension. N Engl J Med. 1997;336:111-117.
13. Fuster V, Steele PM, Edwards WD, et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation. 1984;70:580-587.
14. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992;327:76-81.
15. Badesch DB, Abman SH, Ahearn GS, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004;126:35S-62S.
16. Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005; 111:3105-3111.
17. Sajkov D, Wang T, Frith PA, et al. A comparison of two long-acting vasoselective calcium antagonists in pulmonary hypertension secondary to COPD. Chest. 1997;111:1622-1630.
18. Woodmansey PA, O'Toole L, Channer KS, et al. Acute pulmonary vasodilatory properties of amlodipine in humans with pulmonary hypertension. Heart. 1996;75:171-173.
19. Opitz CF, Ewert R, Kirch W, et al. Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter? Eur Heart J. 2008;29:1936-1948.
20. Soma S, Takahashi H, Muramatsu M, et al. Localization and distribution of endothelin receptor subtypes in pulmonary vasculature of normal and hypoxia-exposed rats. Am J Respir Cell Mol Biol. 1999;20:620-630.
21. Davie N, Haleen SJ, Upton PD, et al. ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med. 2002;165:398-405. (Pubitemid 34118516)
22. Eddahibi S, Raffestin B, Clozel M, et al. Protection from pulmonary hypertension with an orally active endothelin receptor antagonist in hypoxic rats. Am J Physiol. 1995;268(2 Pt 2):H828-H835.
23. Nishida M, Eshiro K, Okada Y, et al. Roles of endothelin ETA and ETB receptors in the pathogenesis of monocrotaline-induced pulmonary hypertension in rats. J Cardiovasc Pharmacol. 2004;44:187-191. (Pubitemid 38982161)
24. Sauvageau S, Thorin E, Caron A, et al. Endothelin-1-induced pulmonary vasoreactivity is regulated by ETA and ETB receptor interactions. J Vasc Res. 2007;44:375-381.
25. Sauvageau S, Thorin E, Caron A, et al. Evaluation of endothelin-1-induced pulmonary vasoconstriction following myocardial infarction. Exp Biol Med (Maywood). 2006;231:840-846.
26. MacLean MR, Docherty CC, McCulloch KM, et al. Effect of novel mixed ETA/ETB antagonists on responses to ET-1 in human small muscular pulmonary arteries. Pulm Pharmacol Ther. 1998;11:147-149.
27. Jasmin JF, Lucas M, Cernacek P, et al. Effectiveness of a nonselective ET(A/B) and a selective ET(A) antagonist in rats with monocrotalineinduced pulmonary hypertension. Circulation. 2001;103:314-318.
28. Dupuis J, Hoeper MM. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur Respir J. 2008;31:407-415.
29. Williamson DJ, Wallman LL, Jones R, et al. Hemodynamic effects of bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension. Circulation. 2000;102:411-418.
30. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelinreecptor antagonist bosentan in patients with pulmonary hypertension: A randomized placebo-controlled study. Lancet. 2001;358:1119-1123. (Pubitemid 32971843)
31. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:846-903.
32. Galiè N, Rubin LJ, Hoeper MM, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): A double-blind, randomised controlled trial. Lancet. 2008;371:2093-2100.
33. McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J. 2005;25:244-249.
34. Provencher S, Sitbon O, Humbert M, et al. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J. 2006;27:589-595.
35. Keogh AM, McNeil KD, Wlodarczyk J, et al. Quality of life in pulmonary arterial hypertension: improvement and maintenance with bosentan. J Heart Lung Transplant. 2007;26:181-187.
36. Barst RJ, Ivy D, Dingemanse J, et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther. 2003;73:372-382.
37. Rosenzweig EB, Ivy DD, Widlitz A, et al. Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol. 2005;46: 697-704.
38. Sitbon O, Gressin V, Speich R, et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004;170:1212-1217.
39. Degano B, Yaïci A, Le Pavec J, et al. Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension. Eur Respir J. 2009;33:92-98.
40. Galiè N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome. A multicenter, double-blind, randomized, placebocontrolled study. Circulation. 2006;114:48-54.
41. Denton CP, Humbert M, Rubin L, et al. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: A subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis. 2006;65:1336-1340.
42. Denton CP, Pope JE, Peter HH, et al. Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. Ann Rheum Dis. 2008;67: 1222-1228.
43. Wilkins MR, Paul GA, Strange JW, et al. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am J Respir Crit Care Med. 2005;171:1292-1297.
44. Galiè N, Badesch D, Oudiz R, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2005;46:529-535. (Pubitemid 41040298)
45. Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension. Results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008;117:3010-3019.
46. Oudiz RJ, Galiè N, Olschewski H, et al. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54:1971-1981.
47. Badesch DB, Feldman J, Keogh A, et al. ARIES-3: Ambrisentan therapy in a diverse population of patients with pulmonary hypertension [abstract]. Am J Respir Crit Care Med. 2009;179:A3357.
48. Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am Respir Crit Care Med. 2004;169:441-447.
49. Barst RJ, Langleben D, Badesch D, et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol. 2006;47:2049-2056.
50. Tracleer prescribing information. South San Francisco, CA: Actelion Pharmaceuticals; 2009.
51. Humbert M, Segal ES, Kiely DG, et al. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J. 2007;30: 338-344.
52. Letairis prescribing information. Foster City, CA: Gilead Sciences, Inc; 2009.
53. McGoon MD, Frost AE, Oudiz RJ, et al. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest. 2009;135:122-129.
54. Thelin prescribing information. Kirkland, Quebec: Pfizer Canada Inc; 2008.
55. Paul GA, Gibbs JS, Boobis AR, et al. Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br J Clin Pharmacol. 2005;60:107-112.
56. Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med. 1992;327:70-75.
57. Tuder RM, Cool CD, Geraci MW, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med. 1999;159:1925-1932.
58. Christman BW. Lipid mediator dysregulation in primary pulmonary hypertension. Chest. 1998;114(suppl 3):205S-207S.
59. Gomberg-Maitland M, Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J. 2008;31:891-901.
60. Rubin LJ, Groves BM, Reeves JT, et al. Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation. 1982;66: 334-338.
61. Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med. 1990;112:485-491.
62. McLaughlin VV, Genther DE, Panella MM, et al. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) in primary pulmonary hypertension. N Engl J Med. 1998;338:273-277.
63. Shapiro SM, Oudiz RJ, Cao T, et al. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol. 1997;30:343-349.
64. Barst RJ, Rubin LJ, McGoon MD, et al. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med. 1994;121:409-415.
65. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334:296-301.
66. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000;132:425-434.
67. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension. The impact of epoprostenol therapy. Circulation. 2002;106: 1477-1482.
68. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension. Prognostic factors and survival. J Am Coll Cardiol. 2002;40:780-788.
69. Olschewski H, Walmrath D, Schermuly R, et al. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med. 1996;124: 820-824.
70. Hoeper MM, Olschewski H, Ghofrani HA, et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. J Am Coll Cardiol. 2000;35:176-182.
71. Hoeper MM, Schwarze M, Ehlerding S, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med. 2000;342:1866-1870.
72. Olschewski H, Simonneau G, Galiè N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347:322-329. (Pubitemid 34815354)
73. Higenbottam TW, Butt AY, Dinh-Xuan AT, et al. Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost. Heart. 1998;79:175-179.
74. Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2003;41:2119-2125. (Pubitemid 36724255)
75. Okano Y, Yoshioka T, Shimouchi A, et al. Orally active prostacyclin analogue in primary pulmonary hypertension. Lancet. 1997;349:1365. (Pubitemid 27197541)
76. Nagaya N, Uematsu M, Okano Y, et al. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. J Am Coll Cardiol. 1999;34:1188-1192.
77. Galiè N, Humbert M, Vachiéry J, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: A randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2002;39:1496-1502.
78. Channick RN, Olschewski H, Seeger W, et al. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension. J Am Coll Cardiol. 2006;48:1433-1437.
79. Tapson VF, Gomberg-Maitland M, McLaughlin VV, et al. Safety and efficacy of iv treprostinil for pulmonary and arterial hypertension: A prospective, multicenter, open-label, 12-week trial. Chest. 2006;129:683-688.
80. McLaughlin VV, Gaine SP, Barst RJ, et al. Efficacy and safety of treprostinil: An epoprostenol analogue for primary pulmonary hypertension. J Cardiovasc Pharmacol. 2003;41:293-299.
81. Lang I, Gomez-Sanchez M, Kneussl M, et al. Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension. Chest. 2006;129:1636-1643.
82. Barst RJ, Galiè N, Naeile R, et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J. 2006;28:1195-1203.
83. Benza RL, Rayburn BK, Tallaj JA, et al. Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension. Chest. 2008;134:139-145.
84. Simonneau G, Barst RJ, Galiè N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. A double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165:800-804.
85. Remodulin prescribing information. Research Triangle Park, NC: United Therapeutics Corp; 2008.
86. Gessler T, Seeger W, Schmehl T. Inhaled prostanoids in the therapy of pulmonary hypertension. J Aerosol Med Pulm Drug Deliv. 2008;21:1-12.
87. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med. 1995; 333:214-221.
88. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 1993;329:2002-2012.
89. Archer SL, Huang JM, Hampl V, et al. Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K channel by cGMP-dependent protein kinase. Proc Natl Acad Sci U S A. 1994;91:7583-7587.
90. Corbin JD, Beasley A, Blount MA, et al. High lung PDE5: A strong basis for treating pulmonary hypertension with PDE5 inhibitors. Biochem Biophys Res Commun. 2005;334:930-938.
91. Revatio prescribing information. New York, NY: Pfizer Labs; 2009.
92. Adcirca prescribing information. Indianapolis, IN: Eli Lilly and Company; 2009.
93. Sastry BK, Narasiham C, Reddy NK, et al. Clinical efficacy of sildenafil in primary pulmonary hypertension: A randomized, placebo-controlled, doubleblind, crossover study. J Am Coll Cardiol. 2004;43:1149-1153.
94. Singh TP, Rohit M, Grover A, et al. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J. 2006;151: 851.e1-851.e5.
95. Galie N, Ghofrani HA, Torbicki A, et al; Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension [published correction appears in N Engl J Med. 2006;354:2400-2401]. N Engl J Med. 2005;353:2148-2157. (Pubitemid 41653106)
96. Bhatia S, Frantz RP, Severson CJ, et al. Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy. Mayo Clin Proc. 2003;78:1207-1213.
97. Ghofrani HA, Rose F, Schermuly RT, et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol. 2003;42:158-164.
98. Hoeper MM, Faulenbach C, Golpon H, et al. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J. 2004;24:1007-1010.
99. Gomberg-Maitland M, McLaughlin V, Gulati M, et al. Efficacy and safety of sildenafil added to treprostinil in pulmonary hypertension. Am J Cardiol. 2005;96:1334-1336.
100. Kataoka M, Satoh T, Manabe T, et al. Oral sildenafil improves primary pulmonary hypertension refractory to epoprostenol. Circ J. 2005;69:461-465.
101. Xu XQ, Jing ZC, Zhang JH, et al. The efficacy and safety of sildenafil in Chinese patients with pulmonary arterial hypertension. Hypertens Res. 2009;32:911-915.
102. Keogh AM, Jabbour A, Hayward CS, et al. Clinical deterioration after sildenafil cessation in patients with pulmonary hypertension. Vasc Health Risk Manag. 2008;4:1111-1113.
103. Galie N, Brundage BH, Ghofrani HA, et al; Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009;119:2894-2903.
104. Aizawa K, Hanaoka T, Kasai H, et al. Long-term vardenafil therapy improves hemodynamics in patients with pulmonary hypertension. Hypertens Res. 2006;29:123-128.
105. Jing ZD, Jiang X, Wu BX, et al. Vardenafil therapy for patients with pulmonary arterial hypertension. A one-year, multicentre, open-label study. Heart. 2009;95:1531-1536.
106. Sildenafil citrate (marketed as Viagra) Information for Healthcare Professionals (7/2005). U.S. Food and Drug Administration Safety Alert. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInfor mationforPatientsandProviders/ucm162862.htm. Accessed December 11, 2009.
107. Gorkin L, Hvidsten K, Sobel RE, et al. Sildenafil citrate use and the incidence of nonarteritic anterior ischemic optic neuropathy. Int J Clin Pract. 2006;60:500-503.
108. Information for Healthcare Professionals: Sildenafil (marketed as Viagra and Revatio), Vardenafil (marketed as Levitra), Tadalafil (marketed as Cialis). Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafety InformationforPatientsandProviders/ucm124841.htm. Accessed December 11, 2009.
109. Maddox PT, Saunders J, Chandrasekhar SS. Sudden hearing loss from PDE-5 inhibitors: A possible cellular stress etiology. Laryngoscope. 2009; 119:1586-1589.
110. Burgess G, Hoogkamer H, Collings L, et al. Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. Eur J Clin Pharmacol. 2008;64:43-50.
111. Wrishko RE, Dingemanse J, Yu A, et al. Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects. J Clin Pharmacol. 2008;48:610-618.
112. Hoeper MM, Taha N, Bekjarova A, et al. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids. Eur Resp J. 2003;22:330-334.
113. Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J. 2004;24:353-359. (Pubitemid 39232254)
114. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006;174:1257-1263.
115. Hoeper MM, Leuchte H, Wilkens H, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Resp J. 2006;28:691-694.
116. Mathai SC, Girgis RE, Fisher MR, et al. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. Eur Respir J. 2007;29: 469-475.
117. Savale L, Sitbon O, Le Pavec J, et al. Addition of sildenafil to first line bosentan therapy in patients with idiopathic pulmonary arterial hypertension-abstrac. Am J Respir Crit Care Med. 2009;179(suppl):A3368.
118. Simonneau G, Rubin LJ, Galiè N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension. Ann Intern Med. 2008;149:521-530.
119. Bendayan D, Shitrit D, Kramer MR. Combination therapy with prostacyclin and tadalafil for severe pulmonary arterial hypertension: A pilot study. Respirology. 2008;13:916-918.
120. Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH) (Compass 2). Available at: http://clinicaltrials.gov/ct2/show/NCT00303459. Accessed August 13, 2009.
121. Hoeper MM, Markevych I, Spiekerkoetter E, et al. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J. 2005;26:858-863.
122. Galie N, Manes A, Negro L, et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J. 2009;30:394-403.